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ABSTRACT 
 
Background. Infection with human immunodeficiency virus-1 (HIV) increases the incidence 
of certain cancers in adults.  Much less is known about the impact of infection on the risk of 
cancer in children.  
Aim. This study aimed to: 1) investigate the association between HIV infection and various 
cancers in children; and 2) compare the outcomes after cancer therapy between children with 
and without HIV.  
Patients and methods. In the first study, the occurrence rates of various malignancies were 
analyzed on a group of 882 children with cancer, where 38 were HIV positive. The 
association between each cancer type and HIV was analyzed using all other cancers as 
controls – excluding those already known to be HIV-associated: Kaposi sarcoma (KS) and 
lymphomas. The association between HIV and outcome after treatment with standard 
cytostatic protocols and anti-retroviral medication was evaluated in a second study, on a 
group of 669 children with cancer out of which 99 were living with HIV. The data were 
processed with Student’s t-test and chi-square test in order to discern the statistical 
significance of the differences recorded. Kaplan-Meyer survival curves were constructed and 
compared by means of log rank (Mantel-Cox) tests. 
Results. In the first study, HIV infection was positively associated with KS - all 10 cases 
were HIV infected, p<0.001- and Burkitt lymphoma (BL) (OR=46.2, 95% CI 16.4–130.3, 
based on 13/33 infected cases). In the second study, the Kaplan-Meyer survival curves do not 
differ significantly by HIV serostatus. However, the proportion of children alive disease-free 
at the end of follow-up, to the total of children in the respective category, is significantly 
smaller in the HIV positive subjects: 32.1% vs. 47.7% (chi-squared, 1 degree of freedom, 
two-tailed p=0.01). Additionally, the proportion of children who died from toxicity 
(including infection due to marked leucopoenia), to the total in their respective group, is 
significantly larger in the HIV positive subjects: 11.9% vs. 0.2% (chi-squared, 1 degree of 
freedom, two-tailed p<0.0001). 
Conclusions. HIV is associated with KS and BL among children with cancer in South Africa. 
The proportion of  children disease-free at end of follow-up is significantly lower in children 
infected with HIV while the proportion of deaths due to toxicity is significantly higher. 
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CHAPTER 1 
 
INTRODUCTION 
 
The AIDS epidemic remains a pervasive threat to the health of the world population. Its 
presence is most intensely felt in Sub-Saharan Africa, which is home to more than two-thirds 
of all persons infected with HIV. Within this region, South Africa has the world’s largest 
population living with HIV in one single country (UNAIDS 2009).  
The existing data document without doubt a higher incidence of a number of malignant 
diseases in adults living with HIV (Engels EA et al, 2008). Some studies found that, among 
the HIV positive population, as many as 40% will be affected by cancer at some moment in 
time (Flint SJ 2009). It is significant that the most frequently encountered cancers in this 
population group are caused by viral infections: Kaposi sarcoma – Human Herpes Virus 8 
(HHV-8), Burkitt lymphoma – Epstein-Barr virus (EBV) and cervical carcinoma – Human 
Papilloma Virus (HPV). It is conceivable that other cancers appear more frequently in people 
with HIV than in those without and might also be associated with viral infections.  
An increase in the incidence of malignancies has been observed not only in adults, but also in 
children with HIV. There is, however, a notable difference in the relative incidence of various 
cancers in these children, between Europe and USA on the one hand, and Africa, on the other 
hand. In resource-rich countries, non-Hodgkin lymphoma (NHL) is found most frequently, 
while leiomyomas and  leiomyosarcomas, associated with EBV infection are second with 
regard to incidence increase (McClain CL 1996). In Africa, Kaposi’s sarcoma is by far the 
most frequent malignancy found in children living with HIV, for reasons which will be 
detailed in the next chapter.  
It is incomparably more difficult to conduct research on cancer in children with HIV than it is 
to do it on adults with HIV. To start with, cancer is much less frequent in children than in 
adults. Further, there are fewer children than adults, living with HIV. Children are mostly 
infected by vertical transmission from their mothers and the transmission rate without 
antiretroviral prophylaxis can be as high as 30%; however, the use of antiretrovirals during 
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pregnancy, combined with other measures, reduces the transmission rate to less than 5%. 
Furthermore, the majority of children infected with HIV would die during the first two years 
of life, if not treated with combined antiretroviral therapy, and thus would not live long 
enough to develop certain malignant diseases. Finally, in Africa, the paucity of cancer 
registries, the often deficient hospital records and the patchy availability of histological 
diagnosis make it difficult to obtain the necessary data. For this reason, most of the studies in 
Africa are based only on small series of cases that may not be representative of the totality of 
cases in the population. 
By collating data from several South African hospital paediatric oncology databases, this 
dissertation assembles a relatively large series of children with cancer and HIV and compares 
them with even larger groups of children with malignant disease but without HIV.  
 
1.1 Aims of this study. Research questions 
The purpose of the study was to investigate the relative frequency of occurrence of various 
childhood cancers, as well as the characteristics of their prognosis, in children with cancer 
infected with HIV in comparison with children with cancer not infected with HIV  
The study was undertaken with the intention to answer two research questions: 
a) What is the relative risk for the occurrence of certain cancers in children living with 
HIV by comparison with children not infected with HIV? 
 It is already established that a number of childhood cancers occur more frequently in 
children living with HIV. Notwithstanding that, a number of differences were noted, with 
regard to the types of cancer encountered more frequently in children with HIV in Africa, 
compared with Europe and US. They will be detailed in the next chapter. This study will 
contribute further data towards defining the association of childhood cancers with HIV in 
African children.  
It is important to note that cancers like KS and BL are closely associated with viral 
infections, as shown in Chapter 2; similarly, a confirmation of strong association between any 
other particular cancer and HIV infection may single out that cancer as potentially being 
induced by a viral infection and indicate a possible benefit of conducting research, both 
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epidemiologic and in laboratory, aimed at identifying the responsible microorganism, as a 
target for cancer prevention. 
The second question to be answered is: 
b) Is the prognosis of cancer significantly different in children living with HIV, from that 
of HIV-negative children? 
While the immune system impairment due to HIV is worsened by the administration of 
cytostatics, thus predisposing the patient to even more severe opportunistic infections and 
death, the effect of HAART may mitigate this immunity deterioration. Certain small studies, 
which will be presented in the next chapter, have reported good results with cytostatic 
therapy and HAART in children with cancer. 
 
1.2 Chapter plan 
The following chapter of this thesis describes the setting in which this research took place, 
with focus on the HIV-AIDS epidemic in South Africa, the paediatric cancer burden of 
disease and the healthcare institutions which are tasked with the diagnosis and treatment of 
childhood cancers. Chapter 3 is a review of the related literature which summarizes the 
findings on the subject of HIV and malignancy, starting with epidemiological data, 
continuing with the study of oncogenesis in HIV infection and going on to explore the 
knowledge regarding the clinical characteristics and the treatment of cancers in children with 
HIV.  
The fourth chapter describes the characteristics of the series of children studied and the 
statistical methods used to analyze the data. Two datasets were analyzed in this study, each of 
them containing findings from a series of children with cancer some of whom also had HIV 
and the majority of whom did not.  The first dataset served mainly to identify the association 
of HIV infection and individual cancers in children, while the second dataset provided also 
information on the prognosis of the two groups. 
The results are presented in the fifth chapter and are discussed in the sixth. The distribution of 
various malignancies is analyzed comparatively in children with and without HIV. The 
prognosis is described by means of comparative rates of various adverse outcomes as well as 
by Kaplan – Meyer survival curves. The discussion focuses on the significance of the 
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findings for the management of similar cases, with reference to data already published. This 
study presents, for the first time in Africa, as far as I could determine, comparative data 
obtained from relatively large series, where all cases were tested for HIV and  their diagnoses 
of cancer were confirmed by histopathology. 
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CHAPTER 2 
 
BACKGROUND 
 
2.1 Status of the HIV epidemic in South Africa 
The Republic of South Africa is situated at the southernmost part of the continent, covering a 
surface comparable with that of Central Europe. Its total population was estimated, for mid-
2011, at 50.6 million inhabitants. Out of these, 31.3% corresponding to 15,8 million, are 
children under 15 years of age. The infant mortality rate is 38/1000. 
The diverse ethnicity of the South African people is best described by the qualification of 
“rainbow nation”, proposed by the Peace Nobel Prize laureate Archbishop Desmond Tutu. 
Approximately 40 million inhabitants are black, belonging to nine major ethnic groups, with 
the remaining 10 million made up mainly of  white, coloured (officially used term for persons 
of mixed ethnicity) and Indian people. 
The HIV-AIDS epidemic started relatively late in South Africa, by comparison with other 
African countries. In 2011 it was estimated that the overall HIV prevalence was 10.6%. This 
figure corresponds to 5.3 million infected persons, the largest number of people living with 
HIV in any single country. Out of the adult population (15 to 49 years of age), 16.6% were 
HIV-positive. Among women attending antenatal clinics the overall prevalence of HIV 
infection was 20% (Shisana O et al 2009). 
The high prevalence of HIV infection among women of reproductive age constitutes a major 
risk for vertical (mother to foetus) transmission of the virus. Without intervention, the rate of 
transmission is as high as 30%. In South Africa, where an estimated 98% of pregnant women 
attend antenatal care clinics, a nation-wide program of prevention of mother-to-child 
transmission (PMTCT) of HIV, by administering zidovudine from 13 weeks of gestation, was 
implemented. It is estimated that the rate of vertical infection was thus reduced to 5% of 
newborns of infected mothers. A further reduction is achieved by prescribing HAART to all 
pregnant women whose CD4+ lymphocyte count is 350 or lower. However, this remains the 
main pathway of acquiring the infection HIV in children: it is estimated that 63.600 new 
infections have occurred in children, in 2011 (DOH SA 2011). According to UNAIDS, in 
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2009, some 330,000 children were living with HIV in South Africa (UNAIDS 2009). The 
figure might be in reality much higher. 
 
2.2 Data on cancer in South African children 
Statistical information regarding cancer in South African children is provided by The South 
African Paediatric Tumour Registry, the only dedicated children’s cancer registry on the 
continent. The annual incidence of tumors in the 0 - 14 years age group varied between 33,4 
and 47,2 per million from 2003 to 2007, a figure much lower than that found in studies from 
other countries. By comparison, in Europe, the annual incidence of cancer in this age group 
was 140 per million in 1990, and increased slowly for the last 3 decades. The contributors to 
this marked discrepancy are, among others: failure to diagnose the cancers, lack of referrals 
to the oncology units and failure to report the cases to the SACCSG registry (Stefan DC et al 
2012). The combined statistics of HIV and cancer in children suggest that an increasing 
number of South African children with malignant disease are also living with HIV. Their 
exact numbers are not reflected by the available data. A synopsis of the diagnoses reported to 
the registry is presented in Table 2.1. 
 
2.3 The South African public healthcare network and childhood cancer 
In South Africa, the majority of children with cancer are treated in the public healthcare 
sector, at tertiary (subspecialist) level. A few patients are in the care of private oncologists or 
surgeons. As there is no paediatric oncologist practising exclusively in private, the number of 
children treated in the private sector is small. There are seven paediatric oncology centres 
covering the whole country: 
 Tygerberg Hospital, academic tertiary unit situated in Cape Town, serves the eastern 
part of the municipality and a number of districts over a radius of 250 km to the east 
of Cape Town, with a population of around 700.000 children, mainly coloured and 
black. An estimated 300.000 children from the Northern Cape Province are also 
covered by Tygerberg Hospital. 
 The Red Cross Memorial Children’s Hospital, also in Cape Town, serves the western 
part of the city and the Atlantic Coast up to 200 km north of the city; it also receives 
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children from the Eastern Cape Province. The hospital’s catchment area has estimated 
2.800.000 children, mainly coloured and black. 
 Universitas Hospital, situated in the centre of the country, is an academic tertiary 
institution serving a children population of over 800.000, mainly black. 
 
 
 
Type of 
cancer 
Year 
Total 
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
Leukemia 146 157 142 177 162 140 162 206 154 139 150 1737 
Lymphoma 69 83 66 98 85 83 88 86 98 78 89 923 
Central 
nervous 
system 
tumours 
62 61 100 78 80 85 106 104 94 82 69 921 
Nephro-
blastoma 
64 85 75 84 104 62 72 94 71 73 61 845 
Neuroblas-
toma 
38 25 3 44 29 30 27 41 29 31 41 372 
Rhabdomyo-
sarcoma 
40 44 35 55 48 41 42 42 57 52 33 487 
Liver 12 7 13 17 17 14 12 8 13 14 16 143 
Sarcoma 58 59 44 73 54 65 64 73 65 43 53 651 
Bone 22 25 20 22 26 3 25 28 34 48 28 309 
Other 
malignant 
diseases 
15 19 16 44 25 26 22 22 16 19 15 238 
Germ cell 
tumours 
20 27 27 24 20 21 20 17 19 15 13 223 
Total 546 592 575 716 648 598 640 723 650 594 568 6850 
 
Table 2.1: Cases reported to the Children’s Tumour Registry, 1997-2007 (Stefan DC et 
al 2012) 
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 Chris Hani – Baragwanath Hospital, main teaching base of the Faculty of Health 
Sciences, University of Witwatersrand in Johannesburg, is situated in the north-
eastern quadrant of the country and serves mainly the black population of Soweto, but 
also the Nort-West province, with a total estimate of 1.600.000 children. 
 Charlotte Maxeke Hospital, also associated with the University of Witwatersrand, 
serves mainly the inner Johannesburg population, with an estimated children number 
of 500.000, mainly black. 
 Steve Biko Academic Hospital in Pretoria, offers health care for the children living in 
the capital, but also for those coming from Mpumalanga and Limpopo provinces, 
adding up to 3 million children, from various black ethnic groups. 
 Inkosi Albert Luthuli Hospital, in Durban, receives referrals from Kwa-Zulu Natal 
province, mainly black children, totalling 2.660.000. 
The paediatric oncologists form the South African Children’s Cancer Scientific Group 
(SACCSG), with regular meetings where scientific and clinical practice issues are discussed. 
The management protocols of various childhood cancers are identical in the various public 
centres, although practice in the private sector is not standardised or monitored. 
The diagnoses are based on the pathology tests and histology evaluations done by the 
National Health Laboratory Services. This nation-wide institution works according to 
uniform standards, audited regularly by national and international accrediting organizations, 
thus ensuring the uniformity in the diagnostic criteria required by studies such as this one. 
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CHAPTER 3  
 
REVIEW OF THE LITERATURE 
 
A most comprehensive review of the published data on the role of HIV as an oncogenic 
factor was published recently by the International Agency for Research on Cancer 
(WHO/IARC 2011). This chapter, however, is not a summary of that valuable monograph. It 
is the result of independent research and evaluation of the literature, with emphasis on the 
studies published in the last 10 years.  
 
3.1 Changes in the incidence of cancers in Africa associated with the HIV epidemic  
The apparently inexplicable apparition of cases of pneumonia caused by Pneumocystis 
jiroveci and of Kaposi’s sarcoma (KS), mainly among homosexual men in San Francisco and 
New York, led to the discovery of AIDS and HIV, at the onset of the ninth decade of the last 
century. It became evident soon that KS and non-Hodgkin lymphoma (NHL) are strongly 
associated with advanced stages of the HIV infection. Statistics from Western Europe and 
USA have since clearly indicated not only a substantial increase of the two types of 
malignancy already mentioned, but also a higher incidence of cervical and anal cancers as 
well as an increased frequency of conjunctival tumours, Hodgkin lymphoma and 
leiomyosarcoma in children (Biggar RJ 2000 in Feigal EG).  
Studies of adult populations in resource-rich countries illustrate convincingly the excess of 
malignancies related to the infection with HIV. A community-based study done in Texas, by 
means of linkage between the cancer register and the HIV register data (Cooksley CD et al 
1999), found an increase in the incidence of cancers associated with the AIDS epidemic, by 
comparison to the general population, of 16.7 times in males and 2.9 times in females (age-
adjusted). Fifteen per cent of the HIV infected group were found to have a malignant disease, 
with an overwhelming predominance of males. While KS, NHL and cancer of the uterine 
cervix were encountered most often, other cancers were also seen more frequently (4 to 5.6 
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times the expected incidence for the general population): Hodgkin lymphoma, non-
melanocytic skin cancer in males and cancer of the colon in females.  
The largest study to date, The HIV/AIDS Cancer Match Study, based on the linkage of 
HIV/AIDS registries with cancer registries in several states of USA, has yielded similar 
findings (Engels EA et al. 2008). Another research group, who looked at a cohort of over 
13,000 people with HIV infection or AIDS in Australia, added to the list of cancers appearing 
more frequently in HIV patients myeloma, leukaemia and lip cancer (Grulich 2002).  Other 
authors quoted even higher figures, of 40%, for the incidence of cancer in the HIV infected 
population subgroup (Flint SJ 2009). These statistic findings have the advantage of being 
supported by reliable and comprehensive registers and, as a consequence, they are a credible 
representation of the influence of the HIV epidemic on the incidence of cancers in adults, in 
resource-rich countries.  
On the background of the above findings, the effect of the HIV epidemic on the apparition of 
cancer in children (0-14 years) from the above geographical areas was found to be, 
predictably, an enhancing one: non-Hodgkin lymphomas, soft tissue tumours, cancer of the 
uterine cervix in adolescent girls, thyroid and pulmonary cancers were found to appear 
significantly more often in children with HIV than in non-infected children (Mueller BU, 
1996, 1998). While NHL was found most frequently, leiomyomas and leiomyosarcomas, 
associated with Epstein-Barr virus (EBV) infection were second with regard to incidence 
increase (McClain CL 1996). Kaposi sarcoma remained, in children, rare by comparison with 
adults living with HIV (Mueller BU 1996, McClain 1996).   
Before considering the influence of the HIV epidemic on the incidence of malignant disease 
in Africa, it is important to acknowledge the characteristics of cancer incidence on the 
continent prior to the advent of the AIDS epidemic.  Two peculiarities, with substantial 
epidemiologic consequences, exist in Africa, by comparison with the rest of the world. The 
first one relates to the incidence of KS. This disease was known, initially, to affect only a few 
elderly people in geographic areas around the Mediterranean basin. Later, with the advent of 
organ transplantation procedures, which required pharmacological immune suppression, the 
disease was seen occasionally in the organ recipients. However, in Africa, before the onset of 
the AIDS epidemic, the incidence of KS was completely different from the rest of the world. 
In large geographical areas situated in Central Africa, extending to Cameroun in the west and 
to Malawi in the south, KS was found to be endemic, with incidence rates greater than 
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6/1000. In these regions, the KS incidence was found to be comparable to that of the cancer 
of colon in Europe (Cook-Mozaffari, 1998). These relatively high rates of pre-existing, 
endemic KS were exacerbated to uniquely high levels under the influence of the HIV 
epidemic. The pre-AIDS endemic KS would also explain why it is much more frequent in 
African children than in children from other regions of the world. 
 The second African characteristic is the relatively high incidence of Burkitt lymphoma, 
which is one of the non-Hodgkin lymphomas, pre-dating the AIDS era. Rates as high as 4 to 
5/1000 were seen in parts of Uganda and Tanzania, while in other geographic areas the rates 
were lower: 0.2/1000 in males and 0.04/1000 in females (Cook-Mozaffari, 1998). These 
figures are considerably higher than European standardized incidence rates, even during the 
AIDS epidemic, which were only 3.94/million (Marcos-Gragera R. et al 2010). 
 Any epidemiologic study on cancer in Africa has to find ways of overcoming the paucity of 
statistical data: The International Association of Cancer Registries counts only 60 members in 
Africa, out of which only 15 are national level institutions, the remaining being hospital or 
city registries (www.iacr.com.fr). These are by no means permanent, their activity being 
often suspended for various lengths of time, due to lack of means or personnel. Only a few 
registers, from 12 African countries in total, reported their data to CI5 (Cancer Incidence on 5 
Continents) database held by IARC and only 5 accepted in group C (2 from Sub-Saharan 
Africa).  
There is definite under-reporting even where registries exist, due to restricted accessibility of 
rural patients to health facilities and limited availability of histopathology services. Further, 
the poor quality of the population census data casts a shadow over the accuracy of any rates 
calculated on the basis of population numbers. With regard to children’s cancer, this is 
usually reported to the adults’ register, thus raising the question whether some data specific to 
children are actually recorded or maybe left aside. The only children’s cancer register in 
Africa is kept by the South African Children’s Cancer Study Group. 
In African adults, the HIV infection has exacerbated, in the first place, the occurrence of KS. 
Comparing the Kampala Cancer Register entries before and after the onset of the AIDS 
epidemic, an increase in the KS incidence from 2.6 to 30.1/100,000 was found in men, while 
in women the increase was from 0 to 11/100,000. The incidence of the cancer of the uterine 
cervix doubled; that of NHL changed only little (Wabinga HR et al 1993). Similar findings 
were published 8 years later, this time in a synopsis of data from Sub-Saharan Africa: the 
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incidence of KS increased the most, with a dramatic reduction in the male/female ratio from 
19:1 to 1.7:1. The risk of NHL in HIV-infected people was lower in the area studied than in 
the developed world. The changes in incidence of the cervical cancer were not significant, but 
the incidence of human papilloma virus infection of the cervix and that of the high-risk 
squamous intra-epithelial lesions were increased. The author noted also the significant 
increase in the incidence rate of the squamous cell carcinoma of the conjunctiva (Thomas JO 
et al 2001). These findings were reinforced in a later case-control study, based on 
histopathological records, done in South Africa (Stein L. et al 2008). A recent review of the 
literature regarding the incidence of cancer in HIV-infected subjects in Sub-Saharan Africa 
found, in case-referent studies, odds ratios ranging from 21.9 (95% confidence interval –CI -  
12.5-38.6) to 47.1 (31.9-69.8) for Kaposi sarcoma and from 5.0 (2.7-9.5) to 12.6 (2.2-54.4) 
for non-Hodgkin lymphoma (Sasco AJ et al 2010). The other findings fell in line with the 
above. 
Data on the influence of the HIV epidemic on the incidence of cancers in children are, 
relative to adults, patchy, with regard to geographical area and time intervals studied. In 
Uganda, the spreading of AIDS has increased the incidence of KS in children by a factor of 
40 (Ziegler 1996). Another case-control study in the same country found that children with 
HIV had a significantly increased probability of acquiring KS (OR = 94.9, 95% CI 28.5-
315.3, based on 36 cases) and Burkitt lymphoma (OR = 7.5, 95% CI 2.8-20.1, based on 33 
cases) but no increase in risk was seen for other cancers (Newton R et al 2001). In Tanzania 
too, a comparison of cancer register records before and after the AIDS era indicate a 
significant increase of the cases of paediatric KS (Amir H et al  2001). In Zambia, a 
comparative review of the histopathological records of cancer in children (less than 14 years 
of age) during the pre-AIDS interval 1980-1982 with the 1990-1992 interval when the 
epidemic was established, found also an increase in the incidence of KS and of 
retinoblastoma. Non-Hodgkin lymphoma, nasopharyngeal carcinoma and rhabdomyosarcoma 
were seen more frequently in the second interval studied but their incidence increase was not 
statistically significant (Chintu C et al 1995). 
In Malawi, the proportion of HIV-positive children in cohorts diagnosed with the same 
malignancy was determined during the periods 1998-2003 and 2005-2008 in two separate 
studies. Sinfield RL et al (2007) reported a review of hospital records, while Mutalima N et al 
(2010) performed a case-control study. According to their research, the infection with HIV 
was associated significantly with KS (Odds Ratio - OR = 93.5, 95% CI 26.9 to 324.4) and 
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with non-Burkitt, non-Hodgkin lymphoma (OR = 4.4, 95% CI 1.1 to 17.9). Burkitt 
lymphoma was endemic in Malawi, with relatively high incidence rates, before the advent of 
AIDS and its occurrence did not appear to be affected by the epidemic. This is an as yet 
unexplained finding, as in South Africa, where Burkitt was relatively rare before the AIDS 
era, it was seen much more often afterwards: the odds ratio for the occurrence of this cancer 
among HIV positive children - versus HIV negative - was calculated at 46.2 with 95% CI= 
16.4-130.3 (Stefan DC 2011). This figure is even higher than the increase in risk found in the 
Ugandan study mentioned above (Newton R 2001).   
The effect of the HIV infection on the incidence of cancer in children in Africa, as depicted 
by the findings from the above studies, is that of a possible modest increase in the incidence 
of a certain number of cancers such as retinoblastoma, nasopharyngeal carcinoma and 
rhabdomyosarcoma, coupled with a substantial increase of KS; Non-Hodgkin (and non-
Burkitt) lymphoma seem to have increased modestly. The findings on the incidence of 
Burkitt lymphoma in children with HIV are contradictory and this contradiction awaits 
further verification and a convincing explanation. There is a clear distinction between the 
patterns of increase in cancer incidence in African HIV infected children and children from 
the rest of the world and the main difference is that KS is much more frequent in Africa than 
elsewhere.  
 
3.2 Oncogenesis in HIV infection 
The list of malignancies which appear more frequently in people infected with HIV is 
extensive. However, only a few cancers, as highlighted in the previous chapter, are highly 
prevalent in this population group: KS, Non-Hodgkin lymphomas and invasive cancer of the 
uterine cervix. They are so often encountered in association with HIV infection that they are 
considered to be AIDS-defining conditions, together with infections like tuberculosis, 
candidiasis, Pneumocystis jiroveci pneumonia and others. It is significant that the above 
cancers are also, almost always, caused by infections: KS is the result of infection with 
Human Herpes-Virus 8 (HHV-8), also known as Kaposi Sarcoma Herpes Virus (KSHV ) 
(Chang 1994), Burkitt lymphoma and other AIDS-associated lymphomas are caused mainly 
by the Epstein-Barr virus (EB) (Epstein MA 1964) and the Human Papilloma Virus (HPV) is 
the agent of the cancer of the uterine cervix (Zur Hausen H 1983). 
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 The mechanisms by which viruses may trigger cancers are not entirely elucidated, but 
essentially they would alter the structure of cellular DNA or the expression of genes involved 
in the control of cell division. Viral oncogenes may be added to the cellular DNA, leading to 
excessive expression of the respective encoded proteins and consequent disturbance of cell 
multiplication. Other viruses may activate cellular oncogenes or inactivate tumour suppressor 
genes. 
It has been established that HIV does not have any of the above properties, but promotes the 
oncogenesis induced by the other viruses mentioned. This effect is due, on the one hand, to 
an inefficient immune surveillance against both oncogenic viral agents and the tumour cells 
they may produce. On the other hand, the HIV-associated chronic hyperactivity of the 
immune system mediated by cytokines stimulates the immune cells’ proliferation, which in 
turn enhances the replication of oncogenic viruses within those cells. Secondarily, the 
cytokines promote the growth of blood vessels in the tumour tissue. The inefficient immune 
surveillance may also explain why other cancers, not known to be associated with infectious 
agents, appear slightly more frequently in HIV-infected children (Flint SJ, 2009).  
As the cancer of the uterine cervix may first be seen towards the end of adolescence, only the 
oncogenic processes associated with KSHV and EBV would be responsible for most of the 
excess of paediatric malignancies associated with HIV. Since its characterization by Chang in 
1994, KSHV was found in transformed epithelial cells in all specimens of KS, but not in 
healthy tissue. A number of viral genes were identified, which may be responsible for the 
tumoural transformation of the vascular epithelium induced by KSHV. Some of these are 
entirely viral genes (i.e. without correspondent in the target cells): K1, kaposin and viral G 
protein-coupled receptor. Others are generating proteins similar to those found in the cell, 
thus deregulating the processes of cell multiplication and apoptosis: viral IL-6, viral 
interleukin 10, viral cc-class chemokines and viral FLICE*-inhibitory protein. A third group 
of genes are involved in maintaining the persistence of the virus through the process of cell 
replication: the gene for Latency-Associated Nuclear Antigen and K-15 (Angeletti 2008).  
The Epstein-Barr virus infects mainly the B lymphocytes. It is one of the most widely spread 
 
 
* FLICE stands for FADD-Like Interleukin 1β-Converting Enzyme, where FADD 
is the acronym for Fas-Associated protein with Death Domain, a protein involved 
in the initiation of the apoptosis process. 
23 
 
viruses in humans, as it infects around 95% of adults worldwide. For most of the time, the 
virus is present in latent form, with its genome integrated in the cell DNA and replicating 
with it when the cell divides. Sometimes the lytic form of the virus will be generated, and it 
would spread to infect other susceptible hosts. Some of the viral genes are active during the 
latency phase, producing proteins which have the potential to induce malignant 
transformation. The genetic lesions identified in the resulting malignant cells include c-myc 
gene rearrangement, bcl-6 gene rearrangement, ras gene mutations, and p53 
mutations/deletions (Angeletti 2008).  Three patterns of gene expression were identified, 
corresponding to three latency types, and to three different malignancy groups of the B cells: 
Burkitt lymphoma, some AIDS-associated lymphomas (primary central nervous system 
lymphomas, diffuse large cell lymphomas, Hodgkin lymphoma, primary effusion 
lymphomas) and leiomyosarcomas (Kutok JL 2006, Bajaj BG 2007). 
Both KSHV and EBV have considerable potential to induce malignancies, but their influence 
is probably not sufficient, as only a fraction of those infected will ultimately develop cancers. 
The concomitant infection with HIV enhances the oncogenetic activity of these viruses. Some 
of the mechanisms responsible for this process have been presented at the onset of this 
chapter; there may be other interactions involved, which will be revealed by future research.  
 
3.3 The influence of the HIV infection on the clinical presentation of malignancies in 
African children 
The immune response deterioration in AIDS might result, in theory, in faster progression of 
the malignant disease. This could be expressed by more advanced or widespread cancers at 
the first presentation, a poorer response to treatment and a reduced survival rate. It is also 
possible that the symptoms and signs of the cancer would be altered by the immune 
suppression, as the immune response is often contributing to generating the signs and 
symptoms of a disease. There is a dearth of information in the literature on these aspects. An 
explanation may reside in the relative rarity of cancer in children coupled with a relative 
rarity of HIV in this age group, with the resulting difficulty of finding enough cases to 
comply with the power requirements of the studies. In most of the world, even those cancers 
whose incidence is increased by AIDS were relatively rare in children before the epidemic 
(and remain rare in those not infected with HIV) and therefore it is not easy to compare their 
AIDS and non-AIDS presentation. In Africa, this comparison might be possible, at least for 
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KS and Burkitt lymphoma, which were endemic even before the advent of the HIV epidemic. 
This endemic presence continues unabated in HIV-negative children, alongside to the 
epidemic form, which is associated with AIDS. In the following paragraphs, the published 
evidence on the effect of AIDS on the clinical presentation of KS and Burkitt lymphoma 
(BL) will be reviewed. 
There are only a few studies that evaluate the clinical presentation of KS in African children 
with HIV and not all of them relate the findings to HIV-negative controls. As their 
methodologies and presentation of results differ substantially, they will be presented one by 
one in this and the following paragraphs. Ziegler and Katongole-Mbidde (1996) analyze 100 
Ugandan children, below 15 years of age, with KS. Out of 63 tested, 49 were found to be 
HIV-positive, but they are not compared with non-infected children. The median age of the 
group at diagnostic was 4 years and the male/female ratio was 1.7:1. The most frequent 
localization of the lesions was in the lymph nodes: 70 cases, versus only 45 cases with skin 
lesions. The radiographs showed chest lesions in 56 children; abdominal lesions were found 
in 11 cases. The authors distinguished three patterns of distribution of the lesions: oro-facial, 
frequently associated with disseminated lymphadenopathy; inguino-genito-anal and isolated 
visceral lesions.  
Amir H. et al (2001) looked at the clinical presentation of KS in 150 Tanzanian children, 
registered in the national cancer register. Out of them, 73 presented with the disease between 
1968 and 1982, before the onset of the AIDS epidemic in Tanzania. The remaining 77 were 
registered during the epidemic, from 1983 to 1995. However, the HIV testing was sporadic 
and the results are not presented. The median age was 2 years in the first group and 3 years in 
the second. The respective male/female ratios were 5.1:1 and 5.4:1. During the first period, 
patients seen were having almost equally often lymph node lesions (47.9%) and cutaneous 
lesions (49.3%), while in the AIDS period, the lymph node localization was less frequently 
seen (31.2%) and the skin was involved more often (53.7%). Further, the skin manifestations 
of KS were mainly limited to the lower limbs in the pre-AIDS era, while thereafter they were 
often disseminated, covering also the upper limb and ears, eyelids and lips.   
Mwanda OW et al (2005), in the context of a retrospective analysis of 91 cases of KS of all 
ages, reports on 15 children included in the study group; 7 were infected with HIV whereas 8 
were not. The children were aged between 6 and 10 years. The HIV-infected children had 
oral/mucosal lesions more frequently (p=0.007) and more often abnormal chest radiographs 
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(p=0.01) than their counterparts. The same subgroup showed an “apparent” trend, but not 
significant, towards respiratory system and skin involvement. 
Sinfield RL et al (2007) compared the clinical presentation in 52 HIV-positive Malawian 
children with KS that of 4 HIV-negative. The median age at the initial consultation was 7.2 
years in the HIV subgroup and 2.3 in the negative subgroup. The male/female ratio was 1.7:1 
in the HIV-positive whereas all 4 non-infected children were male. Lymphadenopathy was 
the presenting complaint in the non-HIV group, while the children with AIDS complained on 
admission of symptoms related to the HIV infection and KS was an incidental finding. All 
pulmonary (2 cases) and abdominal (2 cases) KS was seen in the HIV-positive group. The 
rest of the group had cutaneous lesions. 
Gantt S. et al (2010), in a series of 73 HIV-positive children with KS in Uganda, found a 
male/female ratio of 1.02:1. The median age was 10.1 years; lymph node localization was 
more frequent than skin involvement (25 cases – 59.5% versus 20 cases – 47.6% 
respectively). Those children with lymph node disease were 3.7 years younger than those 
with other distribution of lesions (p=0.01) and their CD4+ count and percentage was 
significantly higher, although remaining in the immune deficiency range of values, even after 
adjusting for age-corresponding CD4+ decrease. The researchers included children up to 18 
years of age in this study and this makes it difficult to compare its results with the other 
analyses summarized above. 
While it is difficult to distil a characteristic clinical picture of KS in HIV-positive children 
from the findings described above, there is evidence pointing to a more disseminated disease 
at presentation (similar with KS in adults) in HIV-infected versus non-infected, including 
more frequent visceral involvement. The question whether HIV does correlate with more 
frequent lymph node involvement than skin involvement by the malignancy cannot be 
answered conclusively from these data. It was clearly seen from studies in adults that in the 
pre-AIDS era, males were predominantly affected, while the epidemic KS shows only a 
slightly higher incidence in males. This is due to the considerable increase of the reported 
incidence of KS in females, who are also comparatively more often infected with HIV than 
males are. The same kind of male/female distribution ratio is seen in children infected with 
HIV, probably reflecting the equal risk of acquiring HIV by vertical transmission at birth. 
The only discordant data regarding this issue are found in the study by Amir et al (2001), 
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with ratios of 5.1:1 pre-AIDS and 5.4:1 afterwards, but in that retrospective series the 
children were only sporadically tested for HIV.   
In contrast with the sparse data on the influence of HIV on the clinical picture of KS, its 
effect on the presentation of BL was analyzed in detail in a well-conducted retrospective 
study in Uganda (Orem J et al, 2009). They looked at the records of 228 children with BL, 
out of which 70 were HIV positive and 158 negative. The mean age was 6.9 years, with no 
statistical difference between the subgroups. The male/female ratio was 1.33:1 in the HIV-
positive subgroup and 1.67:1 in the HIV-negative children (not statistically significant). In 
both groups the most frequent localization of the tumour was facial (71.4% in HIV-positive, 
76.6% in HIV-negative); however, children with retroviral infection had significantly more 
frequent liver and thoracic involvement, as well as lymphadenopathy. As a consequence, 
there were significantly more children presenting in advanced stage (stage D) in the HIV-
positive subgroup compared with the HIV-negative (37.15 versus 20.3%, respectively), with 
the corresponding effect on the survival rates.  
In conclusion, KS and BL, whose endemic variants coexist with their epidemic variants 
associated with AIDS, offer a unique opportunity to assess the effect of HIV infection on the 
course of cancers. The evidence from retrospective studies on these two diseases in children 
with and without HIV in Africa point to a faster progression of the malignancies in the 
presence of immune deficiency, suggested by a larger proportion of more disseminated forms 
involving more often thoracic or abdominal organs. As it will be shown below, the 
consequence of this negative influence is a poorer prognosis. 
 
3.4 Particularities of the management of malignant disease in children with HIV and 
cancer in Africa 
Before discussing the specific issues related to malignancy treatment in children with HIV in 
Africa, it is necessary to review briefly two topics of universal interest in the management of 
such cases. The first one regards the use of standard cytostatic or radiotherapy protocols 
versus low-dose protocols. Cancer chemotherapy is associated with a severe immune 
suppression due to the destruction of leucocytes. In children with a healthy immune system, 
the leucopaenia induced by cytostatics is transient and will redress itself during the intervals 
between therapeutic doses. They are, however, susceptible to severe infections during the 
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neutropenic spells. In contrast, children with an already compromised immunity by HIV 
would not recover but would develop a progressive neutropaenia during the course of their 
treatment (Chanock PJ, Pizzo PA 1995). They are thus even more prone to developing 
infection during cancer chemotherapy. The answer to this complication is, however, not a 
low-dose cytostatic protocol (Spina M 2011, Re A et al 2009, Galicier L et al 2007) but rather 
an efficient infection prevention by controlling the child’s environment, applying strict 
hygiene measures and using well-planned prophylactic antibiotherapy, guided by the 
oncology unit’s cumulative antibiogram and by the knowledge of the infectious agents that 
are usually being encountered in AIDS (Chanock PJ-see above).  
An important role in the management of patients with advanced malignant disease receiving 
chemotherapy is fulfilled by the peripheral stem cells transplant, which assists with the 
reconstitution of the immune system. There is also an increasing interest in using the bone 
marrow transplant with HIV-resistant (naturally or genetically modified) cells as a definitive 
treatment for the retroviral infection (Krishnan A et al 2010). 
Radiotherapy should be given in standard doses, irrespective of the HIV status of the patient. 
It will be, however, associated with increased toxicity, mainly for the mucosa of the digestive 
tract. Further, radiotherapy was clearly shown to reduce the CD4+ cell counts, both in HIV-
negative and positive patients. This reduction is persistent over several years. There are no 
published data yet to support the potential increase in risk for opportunistic infections in HIV 
positive patients who receive irradiation. While there is no evidence to support the initiation 
of HAART at the onset of radiotherapy or before it in such cases, the use of prophylactic 
antibiotics is common (Housri N et al 2010). 
The second topic of general interest for review in this chapter is the role of HAART in the 
management of malignancies among people with HIV infection . Antiretroviral therapy 
reduces the viral load and allows for restoration of the depleted CD4+ lymphocytes and, 
consequently, the immune status of the patient improves. A number of case studies reported 
complete or partial remissions of Kaposi’s sarcoma after initiation of HAART, mostly in 
adults but a few also in children (Feller L et al 2010, Niehues T et al 1999). The shortcomings 
of most of these reports are the small number of cases and short follow-up.  Among the more 
substantial ones is the report by Cattelan AM et al (2005) who have followed up 22 adults 
with KS for a median duration of 40 months (17-78 months) after initiation of HAART. They 
observed a durable complete remission in 18 subjects (91%), a partial remission in 2 and a 
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progression of the disease in a further 2 patients. The complete remission coincided with an 
increase in the CD4+ cells count and a drop in the number of viral copies/ml. In view of such 
findings, it seems logical to consider HAART as the first line of treatment in childhood KS, 
while cytostatics constitute the second line. Caution should be used, however, in conducting 
antiretroviral therapy on patient with KS, as a substantial increase in the volume of the 
lesions may occur after a few weeks of treatment, due to the immune reconstitution 
inflammatory syndrome (IRIS). The reconstitution of the CD4+ cell number stimulates the 
immune system and leads to additional inflammatory reaction around the cancerous lesions. 
Depending on the localization of these lesions, the IRIS may be fatal; the addition of 
chemotherapy will control the process (Leidner RS et al 2005).  
The effect of antiretroviral treatment in NHL including BL is not equally dramatic, but 
definitely beneficial: they enable the administration of a normal-dose cancer chemotherapy 
and thus improve considerably the prognosis of the patients (Kenkre WP and Stock W 2009, 
Magrath I 2009, Blinder VS et al 2008). Cornejo-Juarez P et al (2008) compares 28 patients 
on cytostatics for NHL who had not received HAART with 59 patients on both NHL therapy 
and antiretrovirals; all were treated in the same institution. Only 14.3% of the subjects not 
receiving HAART achieved complete response to chemotherapy, compared with 57.6% of 
those taking antiretrovirals (p≤0.0001). The mean survival time was similarly extended from 
4.8 to 14 months respectively (p=0.01). 
While there is a clearly documented, significant increase in incidence of cervical 
intraepithelial lesions in people infected with HIV, and while cervical cancer is an AIDS-
defining disease, the evidence accumulated so far does not find any significant effect of 
HAART on the incidence of cervical pre-cancerous lesions or on the course of the cervical 
cancer, with or without treatment (Adler DH 2010). All the same, combined antiretroviral 
therapy does not constitute a remedy in non-AIDS-defining cancers. These appear in 
individuals who are infected with HIV but are not necessarily immune- compromised and 
have no indication for HAART. These cancers remain relatively rare in children (as shown in 
the first chapter), although their incidence increased slightly in the AIDS era. 
Finally, the use of HAART in conjunction with cancer chemotherapy calls for increased 
vigilance and careful planning due to possible drug interactions, as both cytostatics and 
antivirals may be metabolized by the same hepatic enzymes (cytochrome P450 group), with 
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consequent increase or decrease in the actions of some of the agents involved (Mounier N et 
al 2009). 
None of the issues presented so far are specific to Africa, but they apply nevertheless to all 
patients treated on the continent. More frequently seen in African children with malignancies 
and AIDS than anywhere else, are tuberculosis, malaria and malnutrition. Tuberculosis is one 
of the AIDS-defining infections, but it is difficult to circumscribe the contribution of the virus 
to the spread of tuberculosis in the absence of systematic HIV testing of children. In 
communities with a high prevalence of tuberculosis, this contribution may be minimal 
(Middelkoop K et al 2008). Irrespective of the potential influence of the HIV epidemic, 
studies have reported a high incidence of tuberculosis in children with cancer in Africa. The 
latest evaluation, done in a South African children’s hospital, found an incidence of 
tuberculosis among children treated for cancer of 9117/100,000/year, which is 22 times 
higher than the overall TB incidence reported in children from a similar background (Stefan 
DC et al 2008). The particularities of the triad formed by tuberculosis, HIV and solid 
malignant tumours in children, as they appeared from an analysis of a series of 18 patients, 
were described by Hadley GP and Naude F (2009): the overall survival in their series was 
33%; they had difficulty in using imaging, including positron emission tomography, to 
identify the tumour spread, as lymph nodes enlarged due to the tumour or tuberculosis or 
simply due to HIV, were generating similar images. The authors used neoadjuvant 
chemotherapy to gain more time to investigate their patients and to improve their nutritional 
status. 
Malaria is widespread in Sub-Saharan Africa and the geographical distribution of the high 
prevalence areas of BL correspond to those of malaria. The co-operation of malaria and 
infection with EBV in the pathogenesis of BL is generally accepted but insufficiently studied. 
For instance, it has been shown that during malarial infection the replication of the virus is 
enhanced, and the treatment of malaria is significantly reducing the viral load (Donati D et al 
2006). On a population level, interventions successful in reducing the incidence of malaria 
appeared to result in a reduction of the incidence of Burkitt (Geser A et al 1989). Malaria and 
BL coexist undoubtedly in numerous children and malarial cure should be achieved before 
chemotherapy; no studies have been found addressing this particular issue. 
 Malnutrition in children with cancer is frequently seen and not necessarily related to AIDS. 
Studies done in Malawi, using anthropometric parameters such as arm circumference, arm 
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muscle area and arm skin fold, found that between 55.1 and 59.3% (depending on the 
measurement used) of the children admitted with malignancies were undernourished. Further, 
44.5% of these children had a height for age below two standard deviations, indicating 
stunting due to chronic malnutrition (Israels T 2008). A further observation of the same 
children during cytostatic therapy showed that the malnourished children had a higher rate of 
profound neutropaenia, resulting in a higher risk of severe infections and death (Israels T 
2009). These observations call for a thorough evaluation of the nutritional status of children 
with cancer on admission – even more so if they are infected with HIV - and a nutrition plan 
established by a dietician with experience in cancer management. 
In conclusion, although HIV does not cause cancer by itself, it strongly facilitates the 
oncogenic action of other viruses: HHV-8, EBV and HPV. This explains the significant 
increase of the incidence of malignancies known to be induced by the above agents. The 
infection with HIV worsens the prognosis of cancers, mainly due to the profound 
neutropaenia during the treatment with cytostatics, which does not recover between the 
courses of therapy. HAART makes possible a better recovery from neutropenia, thus enabling 
the administration of standard chemotherapy protocols. Tuberculosis, malaria and 
malnutrition, much more prevalent in Africa, add to the complexity of cancer management in 
children with HIV. 
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CHAPTER 4 
 
 PATIENTS AND METHODS 
 
The first question asked in this study was whether children infected with HIV who develop 
cancer have a higher risk of occurrence of any particular cancer, when compared with other 
children with cancer but without HIV. Such a finding, beyond the associations already known 
(e.g. Kaposi sarcoma), may suggest an underlying infectious origin of the respective cancer, 
by analogy with Kaposi sarcoma or Burkitt lymphoma, and, should this hypothesis be 
confirmed by future research, a possible avenue may open for preventing that particular 
malignancy. The second question asked was whether the prognosis of cancer in children with 
HIV is different from the prognosis observed in the absence of HIV.  
 
4.1 Study of the association of HIV infection with particular cancers 
The data on HIV and the risk of specific malignancies in children originated from an on-
going study of the comparative odds of various cancers in children with and without HIV 
(please see also “Author’s declaration”). 
 The data were collected from 2005 to 2009, in four South African paediatric oncology 
centres: Tygerberg Hospital in Cape Town, Chris Hani-Baragwanath Hospital and Charlotte 
Maxeke Central Hospital, both in Johannesburg, as well as Universitas Hospital in 
Bloemfontein. The children, aged from 0 to 14 years, had been either referred directly to the 
paediatric oncology unit by clinics, community health centres or private practitioners located 
in the drainage area of the study hospitals, or had been brought by their parents/relatives to 
the emergency rooms of those hospitals, from where their management was taken over by the 
oncologists.  
A departmental admission register was kept, recording the name, age, sex and presumptive 
diagnostic on admission. This register was used to identify patients’ records later for data 
capture. The age, sex, clinical diagnoses, histology results  and HIV test results were 
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retrieved periodically from the archived clinical records of all children admitted with a 
diagnosis of cancer and were entered manually in an electronic database by study 
investigators in each of the above healthcare units. At the end of the study period, anonymous 
data from the databases were sent to The Epidemiology and Genetics Unit, University of 
York, UK, to be analyzed for demographic differences and distribution of various forms of 
cancer between groups with and without HIV infection. It was found subsequently that thirty 
children had benign neoplasms and 27 were diagnosed with non-neoplastic conditions – they 
remained in the statistical analysis, as there was no evidence that their conditions may be 
associated with HIV and their numbers contributed to the size of the comparison group. The 
age and sex distribution of cases was similar in all centers. Out of the 882 children, 38 (4%) 
were HIV infected.  
Viral testing was done by rapid ELISA followed by confirmation with PCR, according to 
uniform national South African guidelines. Only HIV-1 was considered throughout this 
study, since HIV-2 is mostly present in Western Africa (Centers for Disease Control 2009). 
Further, viral clade differences were not considered, mainly because it was beyond the scope 
of this research, but also because there is no evidence that such differences impact on cancer 
risk in HIV-infected people. The children living with HIV were either on HAART at 
diagnosis or were prescribed HAART immediately thereafter.  
All cancer diagnoses were confirmed by histopathological review as part of routine 
procedures at NHLS and coded to the International Classification of Childhood Cancer, 3
rd
 
edition. A central review of pathology specimens was not considered necessary: the 
diagnoses established by NHLS were considered adequate for the present study, as the 
laboratory practice is in accordance with uniform national standards (see also Chapter 2). 
All eight hundred and eighty-two children newly admitted with suspected cancer, during the 
period indicated above, were entered into the study (for 12 the HIV status was unknown and 
their information was not entered in the statistical analysis). Odds ratios for the association 
between HIV and each cancer type were estimated using unconditional logistic regression 
with adjustment for age (by single year), sex, and centre (SAS software). For each cancer 
type, the comparison group comprised all other cancers, excluding Kaposi sarcoma and 
lymphomas, which are already known to be HIV-associated.  
Ethical approval for this research was granted from each centre separately and from the 
Oxford Tropical Research Ethics Committee. 
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4.1.1 Definition of cases and controls 
Cases were children with each one of the cancer types. In order to evaluate the effect of the 
exposure to HIV infection, the odds of HIV positivity in cases were compared with the odds 
in all other children with cancer, serving as controls. The cancers already known to be 
associated with HIV – Kaposi sarcoma and lymphomas - were excluded from controls. 
Controls were admitted to the same hospitals during the same time intervals as cases; their 
number was several times larger than the cases number, thus increasing the precision of the 
results (Grimes 2005).  
 
4.2 Study of the impact of HIV infection on the prognosis of cancer in children 
The second question asked in this dissertation aimed at exploring the effect of HIV infection 
on the prognosis of cancer in children. In order to answer this question, a retrospective cohort 
study was designed, using two cohorts of children admitted to hospital with malignant 
disease, one living with HIV and the other without HIV. It was thus possible to study the 
differences in prognosis only for children (0 to 14 years of age) admitted to hospital, with the 
intention to undergo treatment for their HIV infection and malignant disease. 
The first cohort included eighty-four children HIV positive (the exposed group): these 
patients had been consecutively admitted from January 2002 to April 2010 to the paediatric 
oncology units of Tygerberg Children’s Hospital in Cape Town and Universitas Hospital, 
Bloemfontein, both in South Africa.  The children with HIV were exclusively of black 
African ethnicity: based on the results of previous studies indicating differences in the 
outcome of cancer therapy between various ethnic groups in South Africa (Stefan DC et al 
2009), it was decided to consider only consecutively admitted black African children, without 
HIV, in the second cohort. This cohort (the unexposed subjects) was comprised of 570 
children with malignant diseases, not infected with HIV, consecutively admitted at Tygerberg 
Children’s Hospital as well as at Universitas Hospital, from January 2002 to December 2010. 
The HIV testing result was not registered in 9 cases, and the histology results were missing in 
6 cases; these children were not entered in the study. 
Similarly with the study described in the subchapter 4.1, the HIV testing was done by rapid 
ELISA followed by confirmation with PCR, according to uniform national South African 
guidelines. Only HIV-1 was considered throughout this study and clade differences were not 
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considered (see subchapter 4.1) Further, all cancer diagnoses were confirmed by 
histopathological review according to NHLS routine protocols and coded using the 
International Classification of Childhood Cancer, 3
rd
 edition. The diagnoses established by 
NHLS were considered adequate for the present study, as the laboratory follows uniform 
national standards (see also Chapter 2).  
All patients in both cohorts (exposed and unexposed) were followed up from the date of 
diagnosis until they died, were lost to follow up or to the end of the study (June 2011). While 
the chemotherapy protocols were identical in both centres for any given cancer, all children 
with HIV were additionally receiving HAART, either initiated prior to diagnosis or 
prescribed shortly (within 48 hours) after diagnosis.  
Data were entered in each oncology unit’s electronic database, by data capturers, after each 
discharge from hospital or after each follow-up visit. The following information was 
extracted by the author from the units’ databases and entered onto a Microsoft Excel 
spreadsheet: date of birth, sex, date of diagnosis, diagnosis (confirmed by histopathology), 
HIV status, date last seen, outcome and therapy protocol. The information related to staging 
was not available in most patients. The CD4-positive leukocyte count or the viral load figures 
were not available for most subjects and could not be considered when performing the 
analysis of outcomes. Due to the retrospective nature of the study, no active or standardized 
follow-up procedures could be instituted. 
The outcomes were defined similarly in both centres: alive disease free, alive with disease, 
dead of disease, dead of toxicity, dead of other causes, lost to follow-up in remission and lost 
to follow-up presumed dead. Deaths due to severe infection in children with neutropaenia 
were included, together with deaths from severe side-effects of the medication, under the 
heading “dead of toxicity”. 
Comparative analyses were then carried out on both cohorts, as follows. . Proportions for 
every outcome enumerated above were calculated, separately for HIV positive and negative 
children, for each cancer appearing in both cohorts (exposed and unexposed). Pearson’s chi 
square tests were used to compare proportions in each group and t-tests were used to compare 
means between the groups  
Comparative Kaplan-Meyer survival curves were constructed for each malignancy in both 
groups. Log rank tests were used to compare the time to mortality between the groups.   
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All calculations were done using STATISTICA software and SPSS version 19 (IBM SPSS 
Inc.). 
Ethical approval for this research was granted from each centre separately and from the 
Oxford Tropical Research Ethics Committee. 
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CHAPTER 5 
 
RESULTS 
 
5.1 Association of HIV infection with specific cancers in children 
The association of HIV infection with specific cancers in children was investigated using data 
from 882 children with suspected cancer diagnosed during the time interval indicated in the 
methods section: 84 from Tygerberg Hospital in Cape Town, 79 from Chris Hani-
Baragwanath Hospital, 642 from Charlotte Maxeke Central Hospital in Johannesburg, and 79 
from Universitas Hospital in Bloemfontein. The group consisted of 476 boys, 400 girls, while 
in 6 cases information on sex was missing. Thirty children had benign neoplasms and 27 
were subsequently diagnosed with non-neoplastic conditions. Data on sex, age and HIV 
serostatus are shown in Table 5.1, together with estimated odds ratios (OR) and 95% 
confidence intervals (CI). The age and sex distribution of cases was similar in all centres. In 
Table 5.1, only cancers counting a minimum of 20 cases were included (with the exception of 
Kaposi sarcoma). The result is that numbers in the columns will not add up to the totals 
shown. The restriction to 20 cases is arbitrary, in order to retain a power of the study capable 
to better identify differences between the groups, but even with this precaution, some large 
odd ratios are not statistically significant, and that is an indicator of insufficient power (see 
Chapter 6: Discussion). 
Of the 882 children, 38 (4%) were HIV infected. HIV was associated with Kaposi sarcoma 
(all 10 cases were HIV infected; P<0.001) and with Burkitt lymphoma (OR=46.2, 95% CI 
16.4–130.3; based on 13/33 infected cases). For non-Burkitt NHL, 2/39 were HIV infected 
(OR=5.0, 95% CI 0.9–27.0). Out of 172 children with lymphoid leukemias, only one had 
evidence of concurrent HIV infection (OR=0.4, 95% CI 0.04–2.9). No other cancer type was 
significantly associated with HIV, however, with the small numbers of cases for many types 
of malignancy, the power of the study was insufficient to detect differences for a level of 
confidence of 95% (see Chapter 6: Discussion). 
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Table 5.1: Characteristics of cancer patients and association with HIV infection (Stefan 
DC et al 2011) 
Cancers 
 
Total 
num-
ber 
Sex 
 
Age (years) HIV status Odds ratio 
(95% CI) 
M F Mis-
sing 
Mean Mis-
sing 
+ - Mis-
sing 
Total patients 
 in the study 
882 476 400 6 6.6 13 38 832 12 
Kaposi’s 
sarcoma 
sarcoma 
 
 
 sarcoma 
10 7 3 0 6.4 0 10 0 0 Infinite (P < 
0.001) 
Non-Burkitt  
non-Hodgkin 
lymphoma 
Hodgkin
lymphoma 
40 19 20 1 9.4 1 2 37 1 5.0 (0.9–
27.0) 
Burkitt 
lymphoma 
33 27 6 0 6.2 0 13 20 0 46.2 (16.4–
130.3) 
Hodgkin 
lymphoma 
44 26 18 0 10.5 0 1 43 0 2.3 (0.3–
21.4) 
Lymphoid 
leukemias 
172 105 65 2 6.8 3 1 171 0 0.4 (0.04–
2.9) 
Nephro-
blastoma 
95 49 45 1 3.5 3 2 89 4 1.2 (0.2–
6.1) 
Myeloid 
leukaemias 
65 27 38 0 6.5 1 2 61 2 2.4 (0.5–
11.9) 
Rhabdomyo-
sarcoma 
56 27 29 0 7.7 0 1 54 1 1.2 (0.1–
10.0) 
Neuroblastoma 49 27 22 0 3.2 0 0 49 0 — 
Osteosarcoma 26 18 8 0 12.5 0 0 26 0 — 
Retinoblastoma 25 17 8 0 2.7 0 1 24 0 2.5 (0.5–
34.0) 
Astrocytoma 22 13 9 0 6.7 1 1 21 0 3.9 (0.5–
34.0) 
Cranial 
embryonal 
tumour 
21 12 9 0 6.5 0 0 21 0 — 
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5.2 Outcome after treatment in HIV positive versus HIV negative children with cancer 
The differences in outcome after treatment in HIV positive and negative children with cancer, 
were explored in the second study, described in 4.2, by comparing 570 HIV negative children 
with cancer (87.2%) with 84 HIV positive children with cancer (12.8%). The analysis of the 
outcomes was performed first on the entire study cohort, followed by a comparative analysis 
of HIV positive and negative groups and lastly by a comparison of HIV positive and negative 
subgroups with the same malignancy: Burkitt lymphoma, leukaemia and (non-Burkitt) 
lymphoma. 
 
5.2.1Characteristics of the study cohort 
a) Age and sex 
The mean age in the group studied was 76.6 months and the median 67.5 months. The 
interquartile range was 33 to 118 months. There was a slight difference in the distribution of 
children by sex with 364 males (55.7%), compared to 290 females (44.3%). 
b) Ethnicity 
As discussed in Chapter 4, given that the children with HIV were all black and previous 
studies addressing the outcome of the treatment for cancer in South Africa indicated 
differences associated with ethnicity, the children entered in the group without HIV were also 
black. 
c) Distribution of cancers in the study group 
The whole group included 654 subjects, diagnosed with: leukemia 127 cases (19.4%), brain 
tumors 118 (18%), nephroblastoma 74 (11.3%), lymphoma 60 (9.2%), retinoblastoma 44 
(6.7%), neuroblastoma 34 (5.2%), Burkitt lymphoma 33 (5%) and rhabdomyosarcoma 24 
(3.7%). Kaposi sarcoma was only present in the HIV positive group in 36 cases (5.5%). Some 
of the unclassified tumors as well as cancers observed in small numbers (below 10) were 
grouped in a separate group under “others” (see Table 5.2 and Figure 1). 
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Malignancy Number 
of cases 
Percent 
Brain tumor 118 18.0 
Burkitt lymphoma 33 5.0 
Kaposi sarcoma 36 5.5 
Leukemia 127 19.4 
Lymphoma 60 9.2 
Nephroblastoma 74 11.3 
Neuroblastoma 34 5.2 
Osteosarcoma 27 4.1 
Other 77 11.8 
Retinoblastoma 44 6.7 
Rhabdomyosarcoma 24 3.7 
Total 654 100.0 
 
Table 5.2. Distribution of cancers in the whole study cohort 
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Figure1. The distribution of cancers in the whole study cohort 
 
d) Length of follow-up of subjects studied 
The average follow-up was 21.5 months and the median 11 months, with a standard deviation 
of 25 months). The interquartile range was of 3 to 31 months. 
 
5.2.2 Study of outcomes for the whole group 
The outcome was defined as: alive disease free, alive with disease, died due to toxicity, died 
due to disease, died of unknown or unrelated causes, lost to follow-up presumed dead lost in 
remission. However, due to the small numbers, for comparison purposes, the 7 groups above 
were also merged into 3: alive, dead and lost to follow up. The final outcome was defined as 
the status of the subject at the end point of the study. Most of patients were still alive (around 
53%) with a small number lost to follow up (little above 6%) and just over 41% were dead at 
the end of the study (Tables 5.3, 5.4 and Figure 2). 
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Table 5.3. Detailed outcomes for the study group 
 
 
 
 
 
 
 
 
 
Table 5.4. Final merged outcomes for the whole group 
Outcome Frequency Percent 
Alive with disease 45 6.9 
Alive without 
disease 
299 45.7 
Dead from disease 245 37.4 
Dead from toxicity 11 1.7 
Dead from 
unknown 
14 2.1 
Lost in remission 20 3.1 
Lost presumed 
dead 
20 3.1 
Total 654 100.0 
Merged outcomes Number of cases Percent 
Alive 344 52.6 
Dead 270 41.3 
Lost 40 6.1 
Total 654 100.0 
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Figure 2. Final merged outcomes for the whole group 
 
5.2.3 Comparative analysis of HIV positive and negative groups 
a) Distribution of cancers 
The distribution of the different kinds of malignancies in the two groups is far from identical. 
Kaposi sarcoma was the most frequently encountered malignancy it the HIV positive group, 
followed by Burkitt lymphoma, whereas in the HIV negative group leukemia is the most 
frequent, followed by brain tumours, each amounting to around  one fifth of all cases . Kaposi 
sarcoma was exclusively seen in HIV positive children while the retinoblastoma, 
osteosarcoma, germ cell tumor, liver tumor and chronic myeloid leukaemia were only 
encountered in HIV negative cases (Table 5.5 and Figure 3).  
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Table 5.5. Distribution of the various cancers in the 2 groups (HIV positive versus HIV 
negative children) 
 
 
 
 
CANCER GROUP 
HIV NEGATIVE HIV POSITIVE TOTAL 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
Brain tumours 118 20.7 0 0 118 18 
Burkitt lymphoma 16 2.8 17 20.2 33 5 
Kaposi sarcoma 0 0 36 42.9 36 5.5 
Leukaemia 121 21.3 6 7.1 127 19.4 
Lymphoma 45 7.9 15 17.8 60 9.2 
Nephroblastoma 71 12.5 3 3.6 74 11.3 
Neuroblastoma 32 5.6 2 2.4 34 5.2 
Osteosarcoma 27 4.7 0 0 27 4.3 
Retinoblastoma 44 7.7 0 0 44 6.7 
Rhabdomyosarcoma 23 4 1 1.2 24 3.7 
Other 73 12.8 4 4.8 77 11.7 
TOTAL 570 100 84 100 654 100 
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Figure 3. Distribution of cancers in relation to HIV 
 
 
b) Distribution by sex 
The distribution of subjects by gender shows a male numeric predominance, compared with 
female numbers in the HIV group (Table 5.6 and Figure 4). This difference is statistically 
significant (chi-squared, 1 degree of freedom, two-tailed p=0.02). 
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SEX 
HIV NEGATIVE HIV POSITIVE TOTAL 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
Female 
263 46.1 27 32.1 290 44.3 
Male 
307 53.9 57 67.9 364 55.7 
TOTAL 570 100 84 100 654 100 
 
Table 5.6. Distribution of HIV positive versus HIV negative children, by sex 
 
 
Figure 4. Distribution by sex of the HIV negative and positive groups (columns 
represent percentages out of the total of 654 children) 
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c) Age at diagnosis of subjects in HIV negative versus positive group 
HIV positive patients with cancer tend to be younger (70.6 months average) than HIV 
negative patients with cancer (77.5 months) but the difference is not statistically significant 
(unpaired t-test, two-tailed p-value = 0.186; Table 5.7). 
 
HIV STATUS NUMBER 
CASES 
MEAN AGE 
(MONTHS ) 
STANDARD 
DEVIATION 
NEGATIVE 570 77.53 51.421 
POSITIVE 84 70.62 43.250 
Table 5.7. Mean age in HIV negative versus positive groups 
 
d) Comparison of outcomes in HIV negative versus HIV positive groups 
There was an excess mortality in the HIV positive group (Table 5.8). The differences noted 
are, however, not statistically significant (Pearson’s chi square test, two-tailed p-value = 
0.495). 
 
FINAL OUTCOME 
HIV NEGATIVE HIV POSITIVE TOTAL 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
Alive 304 53.3 40 47.6 344 52.6 
Dead 233 40.9 37 44.0 270 41.3 
Lost to follow-up 33 5.8 7 8.3 40 6.1 
TOTAL 570 100 84 100 654 100 
 
Table 5.8. Final merged outcomes in HIV negative group versus positive group 
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FINAL OUTCOME 
HIV NEGATIVE HIV POSITIVE TOTAL 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
NUMBER 
CASES 
% 
Alive disease free 272 47.7 27 32.1 299 45.7 
Alive with disease 32 5.6 13 15.5 45 6.9 
Died from disease 230 40.3 15 17.8 245 37.5 
Died from toxicity 1 0.2 10 11.9 11 1.7 
Died of unknown cause 2 0.4 12 14.3 14 2.2 
Lost presumed dead 15 2.7 5 5.9 20 3.0 
Lost in remission 18 3.1 2 2.5 20 3.0 
TOTAL 570 100 84 100 654 100 
 
Table 5.9. Detailed outcome comparison between HIV positive and negative children 
with cancer 
 
However, when analyzing the detailed outcomes in the two groups, it appears that the ratio of 
children alive disease-free at the end of follow-up, to the total of children in the respective 
category, is significantly smaller in the HIV positive subjects (chi-square, 1 degree of 
freedom, two-tailed p=0.01). Additionally, the ratio of children who died from toxicity 
(which include children with infection due to marked leucopoenia), to the total in their 
respective group, is significantly larger in the HIV positive subjects (chi-squared, 1 degree of 
freedom, two-tailed p<0.0001). The data are presented in Table 5.9 above. 
e) Survival analysis in HIV negative versus HIV positive subjects 
The comparative survival analysis over the entire follow up period and in all cancer types 
using Kaplan-Meyer curves is shown in Figure 5. The HIV-positive group demonstrates a 
higher death rate in the first year but the difference observed over the whole duration of 
follow-up is not significant (Table 5.10). 
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Figure 5. Comparative survival (in months) of HIV-negative versus HIV-positive 
children with cancer 
 
SURVIVAL CURVES COMPARED CHI-SQUARED P 
Overall survival 0.791 0.374 
Survival during the first year 3.165 0.075 
Children with leukaemia 0.181 0.670 
Children with lymphoma 0.056 0.812 
Children with Burkitt lymphoma 1.130 0.288 
 
Table 5.10. Test of equality of survival distributions for the different exposures to HIV. 
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Even when the test for equality of the Kaplan-Meyer curves was used only for the first year 
of follow-up, where the difference is most obvious, borderline non statistically significant 
values were obtained (Figure 6 and Table 5.10). 
 
Figure 6. Comparative survival of HIV-negative versus HIV-positive children with 
cancer in the first year of follow-up 
 
f) Survival analysis of HIV negative versus HIV positive subjects for single malignancies 
Several cancers appeared exclusively in one of the groups studied: Kaposi sarcoma was 
present only in the HIV-positive children, while brain tumours, osteosarcoma and 
retinoblastoma appeared only in the HIV-negative group. For these cancers, no comparison 
analysis of survival was possible. Further, no such comparative analysis was done for those 
cancers with only one or two cases in either of the groups: rhabdomyosarcoma and 
neuroblastoma. Finally, all 3 cases of nephroblastoma in HIV-positive children were lost to 
follow-up, thus their outcome is not known. Thus, a comparative analysis of survival was 
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performed only for leukaemias (Table 5.10 and Figure 7), lymphomas (Table 5.10 and Figure 
8) and Burkitt lymphoma (Table 5.10 and Figure 9). When compared by means of log rank 
tests, the differences noted between curves did not attain statistical significance due to small 
sample size and lack of power (see Chapter 6: Discussion) 
 
 
. 
 
 
Figure 7. Survival analysis of HIV-negative, versus HIV-positive children with 
leukaemia 
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Figure 8. Comparative survival analysis between HIV-negative and positive children 
with lymphoma 
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Figure 9. Comparative survival analysis between HIV-negative and positive children 
with Burkitt lymphoma 
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CHAPTER 6 
 
 
DISCUSSION 
 
The data presented above add a few details to the understanding of the complex impact of the 
HIV infection on the risk of cancer, the type of cancer and its prognosis in children. The 
literature in this field is far from exhaustive, partially due to the fact that most of the children 
with HIV live in Africa, where it is incomparably more difficult to compile accurate statistics 
and to perform epidemiologic studies, than it is in western populations. In the following 
paragraphs, an attempt will be made to discern the meaning of this study’s findings, with 
reference to other works published to date.  
 
6.1 The association between HIV and certain cancers in children 
The evidence accumulated so far supports the association between several cancers and HIV 
infection in adults: Kaposi sarcoma, NHL, Hodgkin lymphoma, cancers of the uterine cervix 
and anus, and conjunctival squamous cell carcinoma were identified as clearly being more 
frequent in people with HIV than in those without (Bouvard V. et al 2009). They are, 
however, not directly induced by the immunodeficiency virus: other viruses, such as EBV, 
HHV-8 and papillomaviruses are responsible for the malignant process, as described in 
Chapter 3. The evidence for the primordial role of these latter viruses is that their association 
with the cancers mentioned was also detected in people not infected with HIV (Beral V et al, 
1998). HIV, therefore, facilitates the development of certain cancers with other underlying 
infectious causes and so identifying HIV-related cancers provides a way of identifying new 
cancers that may be caused by infections. This was the purpose of the first study described in 
this dissertation. 
The role of HIV in the oncogenic process in children is not as well defined as in adults, 
mostly because the epidemic was not so strong in the countries which have the resources and 
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skills to research this issue adequately. As a result, the findings are based on a limited number 
of cases. For example, Biggar RJ (2000) found that children living with HIV were at an 
increased risk of NHL (based on 42 cases) -  including sporadic Burkitt lymphoma, 
immunoblastic lymphoma and primary lymphoma of the brain -  Kaposi sarcoma (based on 
four cases), and leiomyosarcoma (based on three cases).  
The vast majority of children with HIV are living presently in Africa, where the human and 
infrastructural capacity for research is considerably limited. Moreover, in numerous 
populations on the continent, Kaposi sarcoma and Burkitt lymphoma were endemic before 
the onset of the HIV epidemic, and this disease background may interfere with the efforts of 
evaluating the effect of HIV-AIDS on childhood cancer. Only two epidemiological studies 
have addressed so far the question of the excess risk of cancer in HIV-positive children when 
compared with HIV-negative children. Newton R.et al (2001), in Uganda, found that HIV 
was associated with a higher risk of Kaposi sarcoma and Burkitt lymphoma, against a 
background of an endemic presence of these two diseases. In Malawi, Mutalima N.et al 
(2010) found that in children with HIV, the incidence of Kaposi sarcoma and non-Burkitt-
non-Hodgkin lymphoma was increased, while the results for Burkitt lymphoma were 
statistically not significant. The explanation may be that this disease existed in endemic form 
before the HIV-AIDS epidemic, and the study might not have had the power required to 
detect the change due to HIV infection.  
The endemic form of Burkitt lymphoma does not occur in South Africa, but in the present 
study, “sporadic” Burkitt lymphoma was clearly associated with HIV as it is among adults 
and children in the west (Engels EA et al 2008). Non-Hodgkin, non-Burkitt lymphoma 
deserves a special mention: this group of cancers were observed significantly more often in 
association with HIV infection (Mueller BU 1996, 1998); however, the odds ratio of 5.0 for 
this association was marginally non-significant (95% CI: 0.9-27.0), suggesting that the study 
might not have the required power to reproduce the findings presented in the literature.  Other 
cancer types in children show no significant association with HIV in our study; similar data 
were produced so far by all studies done in Africa.  
 Leiomyosarcoma, which was found to show an increase in frequency in children with AIDS 
in SUA, did not appear related to HIV in this study, neither in other African research 
published so far.  This is even more intriguing when considering that leiomyosarcoma is 
associated with the Epstein-Barr virus, as is Burkitt lymphoma, and consequently an 
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increased frequency of observation of this tumour would be expected. It is, however, a rare 
tumour in children and probably a larger series of subjects would be necessary in order to 
clarify its association with HIV infection. 
The lack of support for the association between HIV infection and acute lymphoblastic 
leukaemia (ALL) may throw a particular light on the hypothetical connection of infections 
and immunity with this haematological malignancy. Kinlen LJ et al (1993, 1995) proposed 
that leukaemia might be the consequence of an infection, aided possibly by the population 
mobility and mixing. Such infectious etiology was demonstrated clearly for leukaemias in 
other mammals (cats, cattle) and in chickens, but not yet in people. Greaves MF et al (1997) 
thought that a relative protection from infections in early childhood, due to higher standards 
of hygiene (the “hygiene hypothesis”) leave the immune system unprepared for later 
infections, which may trigger an inadequate proliferative response leading in some cases to 
leukaemia. Others (Roman E et al 2007, Cardwell CR et al 2008) have, however, found that 
children with leukaemia register an excess of infections in early childhood. It would appear, 
from our findings, that there may not be any correspondence between HIV infection or the 
associated impaired immunity and leukaemic malignancy. In fact, this lack of association of 
poor immunity and leukaemia was noted in immune suppression of other etiologies (Beral V, 
Newton R 1998, Grulich AE et al 2007). 
It is conceivable that children infected with HIV would die before the leukaemia develops; 
this would still leave place for considering an infectious factor in the etiology of leukaemia.  
However, considering the relatively small and statistically insignificant difference in age 
between HIV negative and positive children, found in the second study forming this 
dissertation (Table X), such an asymmetrical distribution of leukaemia cases would suppose 
that HIV positive children who were at risk of leukaemia died at a much higher rate than 
those who were not. So far, there is no evidence to support such death rates. 
The distribution of various cancers in the other study (Table IX and Figure 4) is markedly 
similar to that in the first dataset. Almost 2/3 (60%) of the children living with HIV had either 
Kaposi sarcoma or Burkitt lymphoma. Kaposi sarcoma was exclusively encountered in the 
HIV positive group, while Burkitt lymphoma was 7.2 times more frequent in the children 
with HIV. In contrast  to the above, germ cell tumours, hepatic tumours (grouped under 
“others”) and osteosarcoma  were recorded solely in the HIV negative children, although this 
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may simply have been due to chance, given the relatively low prevalence of HIV among 
cancers other than KS and NHL.  
 
6.2 The impact of HIV infection on the prognosis of children with cancer 
6.2.1 Demographic findings 
a) The average age at diagnosis 
The age at diagnosis average was lower by 6.9 months in the HIV positive group compared 
to the uninfected group; this difference did not attain statistical significance, but the study 
might have been under-powered to detect differences of that magnitude. The available 
literature contains minimal data on the age of onset of malignant disease in HIV positive 
children by comparison with HIV negative. Sinfield et al (2007) found an average age of 2.3 
years in 52 HIV-negative children with Kaposi sarcoma, compared with 7.2 years in 4 HIV-
positive children with the same malignancy. For Burkitt lymphoma, the average age found by 
Orem J. et al (2009) was 6.9 years, with no statistic significant difference between 158 
children not infected with HIV and 70 positive children.                                                                 
b) The male / female ratio 
The ratio of 1.16:1 in the group not infected with HIV (see Table X ) probably reflects the 
generally higher incidence of cancer in males at all ages, which is well documented (Cook 
MB et al 2009). However, this ratio is significantly higher in the children with cancer and 
HIV, at 2.1:1. Considering the published evidence for a 2:1 ratio of vertical transmission of 
HIV to female foetuses versus males (Taha TE et al 2005), this imbalance appears even 
larger. It is possible that the predominance of malignancies known to occur more often in 
boys, in the HIV group, accounts for the unequal representation of the sexes here. 
Considering that Kaposi sarcoma represents almost 40% of the HIV and cancer cases in this 
study and Burkitt lymphoma constitutes over 20%, and that both these cancers are registering 
a male preponderance of 2.3:1 and 3-5:1 respectively, (World Bank 2006, p.294, Boerma EG 
et al 2004), the difference in sex ratios observed might be due to these two diseases. 
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c) The ethnicity 
The HIV-positive children with cancer were exclusively black in this series. The main 
explanation for this may be the high prevalence of HIV in black women of reproductive age: 
30.2%, versus between 3 and 7.1% in women belonging to the other ethnic groups in South 
Africa (SA  DOH survey, 2011). As the main modality of acquiring HIV in children is from 
vertical transmission from their mothers, a predominance of black children with HIV will 
result. 
 
6.2.2 Outcome of treatment 
a) Survival rates 
The overall survival rate in the study of outcome after treatment was 52.6% (HIV positive 
and negative children together). While this figure is much lower than the 79 to 82% survival 
reported from countries like USA, UK or Canada, it is close to published figures from China 
(55.7%) and compares favourably with the 40% survival rate published in a study from India 
(Bao PP 2012, Basta NO 2011). 
The comparison of crude survival figures found a slightly lower probability of survival for 
the HIV infected children than for HIV negative, but the difference is not statistically 
significant. The interpretation of this finding is complicated by the considerable discrepancy 
in the types and distribution of various cancers in the two groups. Notwithstanding that, it is 
important to note that there were comparatively fewer children alive and disease-free in the 
HIV positive group, at the end of follow-up: 32.1% versus 47.7% in HIV negative children 
(χ2=6.544, 1 degree of freedom, two-tailed p=0.01). The percentage of children dead due to 
the toxicity of the treatment is almost 60 times greater in the series with HIV than in the one 
without HIV: 11.9% versus 0.2% respectively (Fisher’s exact test, two-tailed p<0.0001). 
Both these differences are statistically significant, but the numbers of toxicity deaths are 
small. As far as it could be determined, there are no similar findings published in the 
literature.  
In spite of the small numbers, the higher rate of deaths due to toxicity of cancer 
chemotherapy in HIV patients deserves attention. In these children, chemotherapy induces a 
much longer lasting leucopoenia than in HIV negative subjects and thus exposes them to 
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potentially fatal infections. HAART was seen to promote faster remission from leucopoenia, 
thus allowing for a full dose chemotherapy regimen in these patients. The extent to which 
HAART restores the immune response to a level comparable with HIV negative children, 
during cancer chemotherapy is insufficiently studied. In adults, there are several small studies 
indicating comparable results of chemotherapy in HIV negative and HIV positive patients on 
HAART (Suzuki K et al 2010, Blinder VS et al 2008). 
Further, the potential interactions between cancer chemotherapy drugs and HAART are not 
fully understood: both drug categories are metabolized by the same liver enzymatic systems 
(mainly cytochrome P450) and their competing actions on the liver enzymes may result in 
either stronger or weaker systemic effects of some of the drugs (Mounier N et al 2009). All 
children with cancer and HIV in our series received HAART either before or at the onset of 
the cancer therapy. The discrepancy in rates of deaths due to toxicity between the two 
subgroups indicates that, even in the context of present medical progress, HIV infected 
children with cancer remain at very high risk of complications and require close monitoring 
with immediate intervention, should such complications be detected. There is an imperious 
need to broaden our understanding of this kind of drug interactions, as indicated above, if we 
are to improve the outcome of children with cancer and HIV. 
The analysis of the Kaplan-Meyer graphs of survival indicates a comparatively higher 
probability of death in the HIV positive children, in the first months after presentation, before 
the curve joins, even crosses, the HIV negative survival graph; these differences lack 
statistical significance. The survival in both groups stabilizes by about 50 months. However, 
when considering the distinct pattern observed in the first year, separately from the rest of the 
curve, the difference is just close to attaining statistical significance (Table XV and Figure 8). 
This early surplus of deaths in HIV positive children was also signalled by Tukei VJ et al 
(2011). Galicier L. et al (2007) provide a possible explanation of this observation: in a 
mortality analysis of Burkitt lymphoma and AIDS, the deaths occurring early after the onset 
of therapy were due mainly to failure of treatment or to the toxic effects of the medication.  
 
b) Survival analysis in single malignancies 
It was explained in Chapter 5 why only three malignant diseases were suitable for 
comparative survival analysis: leukaemia, lymphoma (non-Burkitt) and Burkitt lymphoma. 
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The analysis was done by means of Kaplan-Meyer curves; while a lower survival for HIV 
positive children was noted in all 3 diseases, none of the differences observed are statistically 
significant.  
As far as it could be ascertained, there are no published data on survival of children with HIV 
and leukaemia, while the data on non-Burkitt lymphoma are obtained on series of less than 10 
cases (Gandemer V et al 2000). This study brings thus an original contribution, with 
compared survival data on larger series of children with these malignancies. 
With regard to Burkitt lymphoma, the analysis of larger series has shown indeed significant 
differences in survival. Orem J. et al (2009) analyzed the outcome of treatment in Burkitt 
lymphoma on 158 HIV negative children compared with 70 HIV positive subjects. Their 
study indicated significantly lower survival odds for the HIV positive group: p=0.023, 
OR=2.22, 95% CI: 1.11- 4.42. Another notable finding was that there were more children 
alive with disease at the end of observation in the HIV positive group (OR 4.84, 95% CI: 
0.99-30.6, p=0.03). 
 
6.3 Original contribution to the knowledge in the domain of childhood cancer and HIV 
a) The findings reinforce the known association between HIV infection and Kaposi sarcoma 
as well as Burkitt lymphoma. The previous two studies which addressed the issue had found 
different results: Newton et al (2001) found a positive association between HIV and Burkitt 
lymphoma, but Mutalima et al (2010) could not confirm it. 
b) The study results cannot support an association between HIV infection and leukaemia. The 
hypothesis that leukaemia has an infectious origin in humans would have been strengthened 
by the finding that the weak immune response induced by HIV increases the risk of that 
haematological malignancy; further research needs to be done on the issue. 
c) Leiomyosarcoma, found significantly more often in children with cancer in studies from 
Europe and USA, was not observed in association with HIV in the two studies described 
here. 
d) The second study presented gives a rate of mortality for black children with cancer 
admitted to hospital in South Africa, based on a relatively large cohort of 882 cases. The rate 
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observed is comparable with similar figures from China and India, but about 30% lower than 
that recorded in resource-rich countries. 
e) The second study found, for the first time in literature, a significantly lower rate of survival 
free of disease for black children with cancer and HIV, compared with other black children 
with cancer but not infected with HIV, while treated with the same protocols. 
f) Also for the first time in literature, a significantly higher risk of death from toxicity of 
therapy was described in black children with cancer and HIV, by comparison with black 
children with cancer but not infected with HIV.  
 
6.4 Considerations on study design and methods 
6.4.1 Referral bias 
It was not intended in the studies presented, to obtain data applicable to the whole population 
of children with cancer. The findings of this research are based only on data from children 
with cancer and HIV admitted to several hospitals in South Africa. They are not 
representative for all children with cancer and HIV in South Africa, for reasons which will be 
detailed here. The following considerations apply to both studies described. To start with, as 
shown at the beginning of this study, the annual incidence of cancers in children, according to 
the South African Children’s Cancer Registry, was between 33.4 to 47.2 per million, whilst in 
Europe in the last decade of the last century it was around 140/million and increasing slowly. 
Children cancer rates were shown to be relatively constant all over the world, mainly because 
they are less determined by environmental and lifestyle factors (which are geographically 
different) but by genetic factors. It follows that the cancer in children in South Africa is likely 
to be significantly under-reported. In this country, children with cancer are referred mostly to 
paediatric oncology units at tertiary hospitals and these units report their cases correctly. It is 
possible thus that the majority of children with cancer do not reach these oncology units. 
Probably the main reason for this lack of referral is either incorrect diagnosis or delayed 
diagnosis, with a number of children dying before they reach the referral centres.  
Other reasons for referral bias may be related to the fear of losing status in the social group 
once the diagnosis of AIDS (associated with a cancer) is revealed. Conversely, children 
known to the healthcare network as living with HIV may be given regular check-ups and thus 
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they may have a higher chance of being diagnosed with cancer and be admitted to hospital 
before dying  
Existing research (Newton et al 2001) found a similar likelihood of seeking medical attention 
for children with various cancers, so the probability of a referral bias by admitting to hospital 
certain cancers to the detriment of others is small. However, it is possible that children with 
the more advanced stages of malignancy are so severely ill that they do not live always to be 
admitted (a variant of the “healthy worker” effect). Finally, families with medical insurance 
(representing 15% of the population) would prefer to admit their children to private hospitals, 
which did not contribute information to the studies presented here. This may also introduce 
an ethnic bias in referrals, as the medical insurance members are predominantly white. 
 Another reason for not extrapolating the findings to the whole paediatric population is that 
the data in the second study were obtained exclusively on black children. It was shown earlier 
in this study that there are differences in outcome of treatment between various ethnic groups, 
so the results may not entirely apply to coloured, Indian or white children. 
 
6.4.2 Other sources of bias, random errors and confounding factors 
Both studies reported in this dissertation are based on data abstracted from medical records. 
In the first study, data were obtained directly from the records, while in the second study 
databases were first created by abstracting data from the records in a contemporary manner, 
during the patient’s hospitalization or follow-up, and the study data were extracted 
retrospectively from these databases. Records used in the studies were created primarily for 
patient care and they are often not sufficiently accurate for research. For instance, it is 
possible that the clinical notes were more accurate in cases of patients with severe diseases. 
Aside from the above, data were incomplete for many patients, e.g. not mentioning the stage 
of the cancer on admission.  
A random error may have originated in the rates of detection by the medical service of 
various childhood cancers, of cancers in HIV positive versus HIV negative children, and the 
specific rate of detection in each centre’s territory. These are unknown and thus impossible to 
adjust for. With regard only to the second study, due to its retrospective nature, it was not 
possible to standardize the follow-up procedures. This may have introduced further random 
errors, as in absence of a planned follow-up procedure, and due to the succession, over years, 
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of several doctors who evaluated the patients, unknown variations might have occurred in the 
evaluation of the outcomes. 
Tuberculosis, often associated with HIV infection but sometimes difficult to diagnose, could 
have been a confounding factor for death from infectious complications due to leucopoenia 
induced by chemotherapy, which in this study is included under “death from toxicity”.    
 
6.4.3 Adequacy of sample size; power of the study 
The sample size was dictated by the availability of hospital databases and therefore it may 
have been inadequate to detect all differences between the HIV positive and negative groups. 
For example, in the study of outcomes described in 5.2, a difference of 7 months was found 
in the duration of follow-up of children with Burkitt lymphoma and HIV when compared 
with children with the same malignancy but without HIV. However, this difference was not 
statistically significant. Power calculation for a p = 0.05, with the standard deviation found 
for the Burkitt subgroup indicate that 105 subjects would have been required in each arm to 
detect such an effect with a precision of 95%. These subjects were not available in this study 
and consequently the observed difference cannot be supported under the study circumstances.    
There is controversy regarding the usefulness of post-study power calculations with the 
purpose of finding the meaning of a non-significant result. Hoenig and Heisey (2001), 
discussing this issue, point out that it is  more useful to compute the power of the study to 
detect the minimum clinically useful difference, rather than the power to detect the observed 
difference, called “observed power”(in this research, however, the aim is not to detect the 
minimum clinically useful difference). The authors demonstrate further that the observed 
power is directly related to the P value. They conclude that the observed power does not 
contribute new information.  
 
6.4.4 Cancer subjects as controls 
The use of subjects with cancer as controls in studies of cancer was analyzed by Linet and 
Brookmeyer (1987) and later reviewed by Lasky and Stolley (1994), with similar 
conclusions. According to Linet and Brookmeyer, the advantages of using cancer controls in 
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studies of cancer cases consist of minimizing recall bias and interviewer bias, the capacity to 
identify specificity of exposure and practicality. While minimizing the bias due to recall or to 
the interviewer did not play any role in the choice of controls in this study, the other two 
characteristics were essential. Linet and Brookmeyer (1987) found that cancer controls may 
be suited for studies where “the question being addressed is whether a specific factor is 
uniquely associated with one or more specific cell types of a particular cancer, one or more 
specific anatomic locations of a particular primary cancer, or a particular cancer versus 
‘cancer’ in general”. In the present study, the “specific factor” is HIV infection, which may 
be associated with a “particular cancer”. Practicality was the other determinant of the choice 
of controls: the data on childhood cancers was readily available, while finding controls with 
other diseases was logistically difficult, as the clinical information on such cases is not stored 
in databases. Moreover, children with other diseases admitted to hospital may have a higher 
ratio of HIV infection than children outside of hospital (some of their diseases, such as 
tuberculosis, may be in fact facilitated by HIV) and thus would introduce a bias in the study. 
Using subjects with cancer on both arms of the study has the additional advantage that the 
same set of data would be found in the records for all subjects. 
The main disadvantage of using cancer controls is that the odds ratios for a particular 
exposure reflect the association of that exposure with a specific cancer by comparison with 
other cancers and not versus the odds of remaining healthy In this study, where the focus is 
on the association between HIV and certain childhood cancers, but not others, the meaning of 
the odds ratio is the desired one. Other disadvantages of using cancer controls presented by 
Linet and Brookmeyer (1987) may result from the unequal distribution of other, known or 
unknown, carcinogenetic factors in the two groups, thus confounding the effect studied. Also, 
the possibility that controls and cases might not originate from the same catchment area may 
be the consequence of more complex cases (or specific types of cancer)  being referred from 
the whole country while less difficult ones only from the hospital catchment area. While the 
biases introduced by different catchment areas do not apply to this study, the statistic effect of 
unknown carcinogens was minimized by using a diversity of cancers as controls. 
Other examples of cancer research using cancer patients as controls are the studies done by 
Smith et al (1988), Newton R et al (1996) and Sitas F et al (1999).   
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6.4.5 Strengths and limitations of the presented studies 
The first study has the advantage of a complete ascertainment both of cancer diagnosis and of 
HIV serostatus within the participating centers. This is in contrast with other African studies 
where this completeness is not attained. Also, as far as it could be established, the series of 
children with cancer, with and without HIV, are among the largest ever analyzed. 
The second study contributes data to areas less researched such as the survival profile of 
children with cancer and HIV compared with that of children with malignancies but not 
infected with HIV.  The study brings an original contribution by providing compared survival 
data on the largest series, to date, of children with leukaemia as well as non-Burkitt 
lymphoma. Additionally, until now, no other figures were published to quantify the lower 
disease-free survival, as well as the higher death rate due to treatment toxicity, in HIV 
positive children with cancer. 
Nevertheless, a number of limitations encountered here may have left their mark on the 
results. To start with, the data on outcome were obtained retrospectively and this made it 
impossible to consider the effect of potential confounders such as the stage of cancer and the 
incidence of tuberculosis, in both groups. However, other studies done in South Africa 
indicate that most of the children enter the health care system in advanced stages of disease 
(Stefan DC et al 2011). Another factor which could not be accounted for, due to missing 
information in the records, was the influence of the HIV stage on the prognosis of infected 
children. 
It is impossible to ascertain in what way the real outcome of children lost to follow-up, 
should it have been known, would have modified the results. While most of losses to follow-
up could be realistically ascribed to death, these numbers cannot be added to the deceased 
numbers. 
Although South Africa is inhabited by a number of ethnic groups, this research was done 
exclusively on black children, limiting thus the extrapolation of findings to the whole of the 
population. A study to address possible differences between children with cancer and HIV 
versus cancer without HIV across different ethnic groups has not yet been done in South 
Africa. 
 Finally, the small size of subgroups with individual cancers restricted the analysis of 
outcome to only three malignancies and impacted on the power of the study. Other barriers to 
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extrapolation were discussed in 6.4.1.; other limitations of the studies were analyzed in 6.4.2 
and 6.4.3.   
 
6.4.6 Alternative approaches to answering the study questions; suggestions for further 
research 
a) The study of association of HIV with particular cancers 
The design used, while having the advantage of being better suited to the analysis of 
relatively rare diseases such as cancer in children with HIV, had insufficient power, with only 
38 cases in the HIV and cancer arm. As a result,the non-Hodgkin, non-Burkitt lymphoma 
could not be significantly connected to HIV infection, although elsewhere in the literature 
there is enough evidence for the association. However, as this is an ongoing study, more 
cases will accumulate in time. 
An alternative approach to the first study would have been a prospective study of two large 
cohorts of children, one without HIV and the other HIV-positive, followed up from birth, 
over 1 ½ decades. Such a design would enable a more precise observation of the incidence of 
various cancers in children with and without HIV infection. The children with cancer, from 
both cohorts, could be entered in prospective studies where the investigations done, the 
treatments instituted and the follow-up protocols could be standardized, to enable a better 
comparison of the outcomes. The results obtained in this manner could have been generalized 
to the whole paediatric population. However, cohorts are not particularly suited to the study 
of rare diseases, and cancer in children is one of the latter.  The main disadvantages of such a 
design are the required large number of participants, with the associated cost, and the long 
time to completion of study. 
Another design which could have been considered was the linkage between the Children’s 
Cancer Registry and the HIV Registry, retrospectively over a number of years, in order to 
analyze the frequency of observation of various malignancies in children with cancer and 
HIV versus children with cancer without exposure to HIV. This design was used with success 
elsewhere (Cooksley CD et al 1999, Engels EA et al 2008); however, the Children’s Cancer 
Registry in South Africa is known to be incomplete, due to underreporting, and it is quite 
possible that the HIV registry is in a similar situation. 
b) The study of association of HIV infection with various outcomes after treatment. 
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A major shortcoming of the second study was the relatively small number of children with 
cancer and HIV, which resulted in insufficient power in the analysis of the outcomes of 
children with the same malignancy. The problem could have been addressed by gaining 
access to databases of more paediatric oncology centres. Another major shortcoming was the 
absence of certain data such as cancer stage or HIV infection stage, and the consequent 
impossibility to estimate their impact on the outcome.  
The outcome after treatment in children with cancer is influenced by the following 
independent variables: 
- Age 
- Sex 
- Ethnicity 
- Nutrition status 
- Associated diseases (e.g. tuberculosis) 
- Type of cancer 
- Stage of cancer 
- Therapy protocol for cancer 
- Supportive therapy (blood transfusion, granulocyte colony growth factor, antibiotics) 
- Follow-up standards 
Further, when assessing the impact of the HIV infection – the exposure - on the outcome of 
cancers after treatment, other variables to consider are the stage of retroviral infection and 
whether it is being treated or not.  
The ideal design of such a study would be a case – control prospective study. Cases could be 
identified from a population-based cancer registry, by linkage with the HIV registry. 
Depending on the availability of cases, the study may be restricted to one or maybe only a 
few cancers, represented in sufficient numbers in both HIV infected and not infected children 
with cancer. The number of participants in the study would be determined by power 
calculations. The selection of cases should minimize the role of confounders, by example 
excluding children with tuberculosis or running a separate analysis for that group. Children 
67 
 
receiving only palliative therapy or no therapy should be included. By recruiting more than 
one control (up to four) for each case, the effect of random error in the control group would 
be minimized.  
In order to reduce the number of independent variables, identical therapy protocols, and 
standardized supportive therapy, should be applied in all participating centres. Further, cases 
and controls could be matched for cancer stage, age, sex and ethnicity. Otherwise, the effect 
of these variables on mortality may be evaluated by logistic regression. The results would be 
expressed in odds ratios for the association of HIV and death or other outcomes considered. 
The outcomes could include the categories used in this study (alive without disease, alive 
with disease, dead from disease, dead from toxicity, dead from unknown cause, lost to 
follow-up presumed dead, lost to follow-up in remission). Kaplan-Meyer curves could be 
obtained after a number of years of follow-up and compared.  
The disadvantage of such a study, assuming that the required registers used for recruiting 
would exist, is the need to follow the participants for a sufficiently long time to assess 
survival. Additionally, the simple inclusion in the study may improve the outcome in children 
with cancer and HIV, who may receive more attention and better care. 
 
An intriguing finding is the absence of the leiomyosarcoma from the study cohorts, whilst in 
the literature it is quoted as being one of the neoplasms encountered much more frequently in 
children with HIV. The finding could be due to a much smaller incidence of leiomyosarcoma 
in black African children and this is an issue awaiting further investigation. Another area for 
investigation could befinding novel ways of mitigating the toxic effects of cancer therapy on 
children with HIV. The second study presented here found a significantly higher proportion 
of deaths from toxicity, including infection on a background of leucopoenia, in children with 
cancer and HIV 
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CHAPTER 7 
 
CONCLUSIONS 
 
a) HIV infection increased the odds for Kaposi sarcoma and Burkitt lymphoma but not the 
odds for leukaemia. 
The first two associations were well known from literature; however, in Africa the increase in 
Burkitt lymphoma in children was not observed by previous studies. The lack of increase in 
the odds for leukaemia in children with HIV does not support the hypothesis that it may have 
an infectious origin. 
b) The overall survival figure in black children, of 52.6% is lower than the 79 – 82% survival 
rates in resource-rich countries 
This figure is close to data found in studies from China and better than survival figures in 
studies from India. 
c) Overall survival rates are marginally lower in HIV-positive black children, without 
attaining statistical significance  
Although marginally lower in HIV positive children than in HIV negative – 47,6% versus 
53.3% respectively  - the difference in survival rates is not statistically significant. The 
analysis of the Kaplan-Meyer survival curves indicates that in the first year of follow-up there 
is a surplus of deaths in HIV positive black children compared with HIV-negative, which was 
borderline non-significant. The literature attributes this finding to the failure of therapy in 
some children or to toxic complications (including infections due to leukopaenia). 
d) Disease-free survival rates in black children with cancer are lower in those infected with 
HIV, while deaths from toxicity are around 60 times higher.  
The rates of disease-free survival are significantly lower in black children with cancer and 
HIV (32.1% versus 47.7%). Additionally, deaths from treatment toxicity are significantly 
higher (almost 60 times) in the HIV positive group, although the numbers in both groups are 
relatively low. 
e) Kaplan-Meyer survival curves of black children with HIV were not found to differ 
significantly from those of black children without HIV, for the same type of cancer 
Kaplan-Meyer survival curves were calculated for leukaemia, lymphoma and Burkitt 
lymphoma. When compared by means of the log-rank test, the differences between the curves 
for HIV positive and negative children were not statistically significant.  
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f) Overarching conclusions 
The first study reinforces the finding that children with cancer and HIV have an excess of 
Kaposi sarcoma and Burkitt lymphoma, when compared with other children with cancer but 
not infected with HIV. The study did not support other correlations between particular 
cancers in children and HIV infection, which, if found, might have indicated a presumptive 
infectious aetiology of the respective cancers. Differences observed when comparing the 
survival of HIV positive black children with cancer, with that of HIV negative black children 
with same malignancies, treated with the same protocols of cytostatics and HAART, were not 
statistically significant. Notwithstanding that, HIV positive black children with cancer are 
more susceptible to treatment toxicity and infections and require a sustained effort to prevent 
these complications during treatment. Less black children with HIV will survive disease free 
than their HIV negative counterparts with same cancers. 
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